Early Drug Launches Off To a Strong Start So Far in 2013
This article was originally published in The Pink Sheet Daily
2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.
You may also be interested in...
IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.